Cerebellum

10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain

Retrieved on: 
Thursday, December 7, 2023
10x Genomics, Alzheimer's disease, NIA, Brain, Research, Cerebellum, DNA, Hope, Hippocampus, Stroke, Doctor of Philosophy, Genomics, Neuroscience, National Institute on Aging, Alcohol-related dementia, Epigenome, NIH, Neurodegenerative disease, DSM-IV codes, News, Biology, Medical imaging

PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.

Key Points: 
  • PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.
  • "Our goal is to provide researchers with a highly detailed genetic map of the damage caused in neurodegenerative disorders," said Andrew B. Singleton, Ph.D., NIH CARD director.
  • NIH CARD scientists aim to produce high-quality, standardized and harmonized datasets that can be integrated with other modalities, like long-read DNA sequencing.
  • NIH CARD is a collaborative initiative of the National Institute on Aging (NIA) and National Institute of Neurological Disorders and Stroke.

AIRAmed Receives FDA 510(k) Clearance for Its AIRAscore Brain Volumetry Software

Retrieved on: 
Tuesday, September 19, 2023
FDA, Data Management, Technology, Mental Health, General Health, Medical Devices, Hospitals, Neurology, Artificial Intelligence, Science, Biotechnology, Software, Other Science, Health, Research, Tissue, Learning, Anatomy, Health care, Neurodegenerative disease, Deep learning, DSM-IV codes, Food and Drug Administration, Pons, Dementia, Woman, Radiology, Parkinson, Teaching hospital, CDC, IT, MRI, Cerebellum, Patient, Myenteric plexus, Physician, Reading, Frontotemporal dementia, Artificial intelligence, Airam Cabrera, CSF, White matter, Ageing, Diagnosis, FTD, Alzheimer's disease, Food, Hippocampus, Disease, Medical imaging

German medical technology company AIRAmed has announced U.S. Food and Drug Administration 510(k) clearance of AIRAscore, a medical image management and processing system providing relevant brain volumetry data to assist physicians in early detection of Alzheimer’s and other dementias.

Key Points: 
  • German medical technology company AIRAmed has announced U.S. Food and Drug Administration 510(k) clearance of AIRAscore, a medical image management and processing system providing relevant brain volumetry data to assist physicians in early detection of Alzheimer’s and other dementias.
  • AIRAscore uses deep learning and artificial intelligence (AI) technology to provide quantitative assessment of brain volume with objectively verifiable data using standard MRI brain scans in as little as five minutes.
  • “With AIRAscore, we are now offering physicians a highly precise, quantitative tool for the rapid detection of areas with a brain volume below the normal range.
  • The software is extremely affordable and can be configured by a hospital’s or radiology facility’s IT department in less than an hour.

PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application

Retrieved on: 
Monday, September 18, 2023
LC-MS/MS, Rat, University, Partnership, CSE, Cerebrospinal fluid, Liquid Tension Experiment 3, The 20/20 Experience – 2 of 2, Serum, Anxiety, Pons, Prefrontal cortex, FSE, Research, Cerebellum, CSF, Experiment, Chronic pain, Pharmacology, Olfactory bulb, Pharmaceutical industry, Medical imaging, Vaccine, Brain, CBD

The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats.

Key Points: 
  • The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats.
  • The primary objectives of this study include:
    Objective 1: Investigating the potential of sol-gel technology for rapid delivery of CBD to the brain.
  • This includes assessing the amounts achieved, regional distribution, and time course of CBD uptake in the brain (Experiments 1 and 2).
  • Experiment 3: Building upon the outcomes of Experiment 1, the study will assess intranasal CBD doses that yield significant brain exposure in rat models of anxiety and chronic pain.

2U CEO Chip Paucek Joins SponsorUnited's Board of Directors

Retrieved on: 
Thursday, August 24, 2023
Cerebellum, Software as a service, Partnership, Goldman, Ernst & Young Entrepreneur of the Year Award, Marketing, 2U, University, Petr Paucek, Intelligence, Entrepreneurship, Ernst, Sport, EdX, Management

STAMFORD, Conn., Aug. 24, 2023 /PRNewswire/ -- SponsorUnited, the leading global sports and entertainment intelligence platform, delivering actionable data and insights to build stronger marketing partnerships, is pleased to announce the appointment of Christopher "Chip" Paucek to its Board of Directors. Paucek's vast experience as a visionary entrepreneur and CEO will catalyze SponsorUnited's growth and strategic direction.

Key Points: 
  • Paucek's vast experience as a visionary entrepreneur and CEO will catalyze SponsorUnited's growth and strategic direction.
  • "I've known Chip since the early days of 2U and I was deeply inspired by his mission," said Bob Lynch, Founder and CEO of SponsorUnited.
  • Paucek has been recognized for his dedication to creating a better future for all through the power of high-quality online education.
  • Paucek's most recent role prior to co-founding 2U was serving as the CEO of Smarterville Inc.–the company behind Hooked on Phonics–from 2007-2008.

BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Monday, May 22, 2023
Canavan disease, Natural history, Urine, In vivo magnetic resonance spectroscopy, PALO, Brain, DSM-IV codes, Biomarker, Cerebrospinal fluid, NAA, MRI, Magnetic resonance imaging, Cerebellum, Patient, Physician, DSMC, Data, Cancer, White matter, CSF, Hospital, FDA, Massachusetts General Hospital, Therapy, Medical imaging, Pharmaceutical industry, Vaccine, Canavan

“Canavan disease is a rapidly progressive, rare neurological disease that affects children from birth and has no treatment options beyond supportive care.

Key Points: 
  • “Canavan disease is a rapidly progressive, rare neurological disease that affects children from birth and has no treatment options beyond supportive care.
  • The changes in key biomarkers, brain myelination and – critically – clinical function observed in children receiving BBP-812 in our study are compelling, and as we continue to advance our program we are hopeful that we will see outcomes that make a meaningful difference in the lives of children with Canavan disease and their families,” said Genevieve Laforet, M.D., Ph.D., vice president of clinical development at Aspa Therapeutics, the BridgeBio affiliate that is developing BBP-812 for Canavan disease.
  • “We are beyond grateful to the children and their families who are participating in CANaspire as well as the study investigators, who together are making it possible to explore the potential of BBP-812 as a therapy for Canavan disease.
  • Across individual participants, percent decreases in NAA from baseline ranged between 70% and 95% in cerebrospinal fluid (CSF), 29% and 88% in urine, and 8% and 75% in brain (by magnetic resonance spectroscopy)
    All participants in the CANaspire trial had urine NAA levels consistent with typical Canavan disease prior to receiving BBP-812.

Memories may be stored in the membranes of your neurons

Retrieved on: 
Tuesday, May 9, 2023
Neocortex, Synapse, Learning, Neuron, Chemistry, Membrane, Synaptic, Research, Protein, Skull, Cerebellum, Brain, Memory, Cell, Hippocampus, Computer data storage, Medical imaging

Its information processing capabilities are what allow you to learn, and it is the central repository of your memories.

Key Points: 
  • Its information processing capabilities are what allow you to learn, and it is the central repository of your memories.
  • Research from our team of biophysicists, physical chemists and materials scientists suggests that memory might be located in the membranes of neurons.
  • The changes taking place between these two membranes, commonly known as synaptic plasticity, are the primary mechanism for learning and memory.
  • These include changes to the amounts of different proteins in the membranes, as well as the structure of the membranes themselves.

Dr. Maria Elena Bottazzi and Dr. Huda Zoghbi Inducted into the Texas Women's Hall of Fame at 2023 Gala

Retrieved on: 
Thursday, March 2, 2023
DRS, Quality of life, Woman, DSM-IV codes, Empowerment, Texas Women's Hall of Fame, Baylor College of Medicine, Mentorship, Hospital, Cerebellum, Baylor University, Rett syndrome, National school, Gene, Breakthrough Prize, Howard Hughes Medical Institute, Nobel Peace Prize, Texas Children's Hospital, COVID-19, Lone Star Distinguished Service Medal, Dysphagia, Neuron, Breakthrough Prize in Life Sciences, Commerce, Texas Women, Education, MECP2, Kavli Prize, SCA1, Tropical medicine, Nursing, Pharmaceutical industry, Fame

HOUSTON, March 2, 2023 /PRNewswire/ -- Texas Children's Hospital and Baylor College of Medicine are proud to announce that Drs. Maria Elena Bottazzi and Huda Zoghbi were honored today by the Greater Houston Women's Chamber of Commerce (GHWCC) and inducted into the Texas Women's Hall of Fame. The Texas Women's Hall of Fame recognizes outstanding women who have contributed significantly to the advancement of women and improved the quality of life for future generations of Texas women.

Key Points: 
  • Maria Elena Bottazzi and Huda Zoghbi were honored today by the Greater Houston Women's Chamber of Commerce (GHWCC) and inducted into the Texas Women's Hall of Fame.
  • The Texas Women's Hall of Fame recognizes outstanding women who have contributed significantly to the advancement of women and improved the quality of life for future generations of Texas women.
  • "It is a great honor to be inducted in the Texas Women's Hall of Fame", said Dr. Maria Elena Bottazzi.
  • "I am so honored to be named to the Texas Women's Hall of Fame along with so many other accomplished women in Houston.

Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases

Retrieved on: 
Tuesday, January 10, 2023
IND, Disease, Spinal cord, CFA, Tissue, Heart, AAV, Duchenne muscular dystrophy, FA, HSV, Solid, Conference, Capsid, Cerebellum, Tropism, NHP, Investigational New Drug, Duchenne, Research, Heart failure, Liver, FXN, Cardiac muscle, Investment, BAG3, Pharmaceutical industry, Management, Vaccine, Agriculture, Hospital

CHARLESTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today outlined its strategic priorities for 2023. These announcements are being made in advance of Solid’s presentation at the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 12 at 9:00 am PT.

Key Points: 
  • “The Solid leadership team has deep expertise in precision genetic medicine, and our diversified pipeline targets diseases with high unmet need, strong scientific rationale, and significant commercial potential.
  • Solid remains focused on developing next-generation AAV capsid libraries with two strategies designed to enhance cardiac and skeletal muscle tropism.
  • Clear mechanistic rationale between genetic BAG3 insufficiency and myofilament damage, poor contraction and heart failure
    Solid’s construct candidates utilize the AAVrh74 capsid and cardiac specific promoter.
  • In early nonclinical studies, the specific capsid and cardiac-specific promoter combination increased cardiac expression while reducing expression in the liver.

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022

Retrieved on: 
Tuesday, December 27, 2022
MWF, White matter, CSO, Calprotectin, ICH, Pharmacokinetics, ADAS, Disability, Board of High School and Intermediate Education Uttar Pradesh, New Drug Application, Thalamus, Principal, GLP, SPMS, Inflammation, BWH, Neurology, Alzheimer's disease, Toxicology, Male, Timed, Trial of the century, Pharmacist, CD, R, Disease, Research, Patient, Cerebellum, Infection, Safety, Expanded Disability Status Scale, PET, FDA, Therapy, IND, EDSS, CMSC, EA, PIND, NSCLC, MD–PhD, Doctor of Philosophy, Pharmaceutical industry, Vaccine, Management, MD, Foralumab

LONDON, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2022.

Key Points: 
  • LONDON, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2022.
  • These protocol amendments or revisions are intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.
  • These results confirm the previously reported data, from the first SPMS patient after three months of treatment of the first SPMS patient.
  • For the six months to 30 June 2022 the consolidated Group made a loss of $8.3m (six months to 30 June 2021: $17.0m).

Sandhoff Disease Drug Research Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs Featuring IntraBio, Sanofi, Polaryx Therapeutics, & Azafaros - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Health, Pharmaceutical, News, GM2 gangliosidoses, Therapy, Glucose, GSL, Clinical trial, NDA, HIV disease progression rates, Sanofi, II, Technology, III, Discovery, Tay–Sachs disease, Cell death, Acquisition, Safety, Brain, Cerebellum, Pharmaceutical industry, Sandhoff disease

The "Sandhoff disease - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sandhoff disease pipeline landscape.

Key Points: 
  • The "Sandhoff disease - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sandhoff disease pipeline landscape.
  • The assessment part of the report embraces, in depth Sandhoff disease commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Sandhoff disease R&D.
  • The companies which have their Sandhoff disease drug candidates in the most advanced stage, i.e.